On the morning of March 30, our Chairman Shi Yuanyuan, Chief Scientist Wang Jianxun, Head of Sales Yang Borui, Assistant to the Chairman Wei Zheng, and Deputy Head of R&D Sun Rui visited Suzhou Fundamenta New Drug Development Co., Ltd. (hereinafter referred to as "Fundamenta") for exchange and discussion. Li Jun, Founder and CEO of Fundamenta, Liu Kaichun, Head of R&D, and Ji Chenxia, Assistant to the General Manager, extended a warm welcome and held a symposium.

During the meeting, the Shenzhen Cell Valley and Fundamenta teams provided detailed introductions to their respective corporate development, core teams, R&D and production pipelines, and core technological advantages, and explored future cooperation models. Fundamenta is a high-tech enterprise focused on innovative drug R&D. Its successfully developed This CAR-T universal CAR-T platform technology employs proprietary intracellular membrane protein retention technology, which not only fundamentally avoids the off-target risks of gene editing but also features a manufacturing process nearly identical to autologous CAR-T ("instant conversion"), utilizing a single viral vector to simultaneously achieve CAR expression and elimination of GvHD.

Dr. Li Jun stated that the company's universal CAR-T 2.0 version plans to adopt Shenzhen Cell Valley's retroviral vectors to create a new universal CAR-T ecosystem. Shenzhen Cell Valley has accumulated extensive experience in industrial-scale retroviral vector production, possesses a professional R&D team, and has a comprehensive process solution. It can provide a full range of services from retroviral vector design and modification, vector production, to cell manufacturing and preparation.

About Suzhou Fundamenta New Drug Development Co., Ltd.

Founded in July 2012, Suzhou Fundamenta New Drug Development Co., Ltd. focuses on the development and clinical application of CAR-T-led tumor immunotherapy drugs. The company possesses domestically leading core technology platforms for plasmid DNA production, lentiviral vector production, CAR-T molecular design/validation/production, and quality control of cell drugs, along with a comprehensive quality assurance system. Based on these platform technologies, the company has completed preclinical research on two dual-target CAR-T cell drugs for hematological malignancies. The company also has a presence in solid tumors, with multiple highly innovative CAR-T R&D projects targeting solid tumors. Located in Wujiang, Suzhou, the company is constructing a 3,600-square-meter CAR-T cell preparation facility, molecular biology and cell biology laboratories, and a state-of-the-art quality control laboratory, capable of providing high-quality and effective cellular immunotherapy support for patients with hematological malignancies and solid tumors.